Prestige Management Doubles Down On Share Purchase After Setbacks
Recent Fall In Stock Price ‘Doesn’t Reflect Potential Value’ Insists CEO
Still reeling from the EMA’s recent rejection of its biosimilar trastuzumab candidate, Prestige BioPharma’s management have bought up more shares in the company, insisting that the “recent fall in stock price doesn’t reflect the potential value” of the firm.
